SNAP-8
An eight-amino-acid extension of Argireline marketed as a more potent topical expression-line treatment. Evidence is supplier-generated.
Skin & Cosmetic
Argireline
The best-known "topical Botox" peptide. It does have a published mechanism and some small clinical studies, but the effect size is modest and the trials are industry-run.
Overview
Botulinum toxin stops muscles contracting by cutting a protein that nerve endings need to release their signal. Argireline is a short peptide that mimics part of that same protein and gets in the way of the machinery assembling, without cutting anything. The effect is far weaker than the injected toxin, and the harder question is whether a peptide applied to the skin surface reaches the muscle underneath at all.
Acetyl hexapeptide-8 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2), mimicking the N-terminal region of SNAP-25. Competes with SNAP-25 for a position in the SNARE complex, destabilising vesicle fusion and reducing catecholamine and acetylcholine release at the neuromuscular junction in vitro. Topical delivery to the level of facial musculature is the principal limitation — the peptide is hydrophilic and larger than the generally cited stratum corneum penetration threshold. Small industry-sponsored studies report reductions in wrinkle depth on the order of 10–30% over 4–8 weeks by image analysis; independent replication with blinded clinical endpoints is sparse.
Research areas
Expression linesTopical anti-ageingSNARE biology
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Topical 10% acetyl hexapeptide-8 solution applied twice daily for 30 days with wrinkle depth measured by image analysis | Blanes-Mira et al., International Journal of Cosmetic Science 2002 |
Trial status
Small, largely industry-sponsored topical studies with instrumental endpoints. No large independent randomised trial.
Reported safety signals
- Well tolerated topically; irritation is uncommon.
- It is a cosmetic ingredient, not a drug, and is not a substitute for or equivalent to botulinum toxin.
- Injection has no published basis and no safety data.
Common questions
Does Argireline work like Botox?
It targets the same machinery, but the comparison is generous. Botulinum toxin is injected directly into muscle and enzymatically destroys its target. Argireline is applied to the skin surface, competes reversibly, and has to cross the stratum corneum to reach anything relevant. Reported effects are small.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →